This research aims to elucidate the underlying molecular mechanisms and signaling pathways, establishing a theoretical foundation for considering HMGB1 as a novel therapeutic target for CRS-related anxiety and depression and providing clear guidance for future clinical applications. This evidence concerns the gene HMGB1 and congenital rubella syndrome.